Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
ConditionUrothelial Carcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorPeking University Cancer Hospital & Institute
About this trial
To evaluate the ability of \[68Ga\]N188 to detect nectin-4 overexpression in patients with urothelial carcinoma, especially in patients with recurrent or advanced bladder cancer.
Eligibility criteria
Qualifiers
18-75 years old, male or female;
Heart function is normal;
Normal heart function;
Estimated survival ≥12 weeks;
Disqualifiers
Serious abnormality of liver, kidney and blood;
Pregnant patients;
Pregnant and lactation women;
Trial design
Treatments tested in this trial
- 18F-FDG
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov